Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The objective of this study was to describe and analyze the clinicopathological features of primary choriocarcinoma (PCC) observed in male patients treated at the Samsung Medical Center between 1996 and 2020. Materials and Methods We reviewed the clinical records of 14 male patients with PCC retrospectively to assess their demographic, histological, and clinical characteristics at the time of diagnosis as well as identify the treatment outcomes. Results The median age of the patients was 33 years. The primary tumor site was the testicles in seven cases (50%), the mediastinum in six cases (43%), and the brain in one case (7%). The most common metastatic site was the lungs (79%), followed by the brain (43%). All patients with PCC received cytotoxic chemotherapy. Twelve patients had records of their response to cytotoxic chemotherapy; of these 12 patients, eight (8/12, 67%) achieved an objective response, and four (4/12, 33%) achieved stable disease response as the best response during chemotherapy. Conclusion It is known that most male PCC patients eventually develop resistance to cytotoxic chemotherapy and die. Factors such as poor response to chemotherapy, high disease burden, brain metastasis, and hemoptysis at the time of diagnosis are associated with shorter survival time in male PCC patients. Programmed death-1/programmed death-ligand 1 blockade therapy can be a salvage treatment for chemotherapy-resistant male PCC patients.
Abstract
Purpose The objective of this study was to describe and analyze the clinicopathological features of primary choriocarcinoma (PCC) observed in male patients treated at the Samsung Medical Center between 1996 and 2020. Materials and Methods We reviewed the clinical records of 14 male patients with PCC retrospectively to assess their demographic, histological, and clinical characteristics at the time of diagnosis as well as identify the treatment outcomes. Results The median age of the patients was 33 years. The primary tumor site was the testicles in seven cases (50%), the mediastinum in six cases (43%), and the brain in one case (7%). The most common metastatic site was the lungs (79%), followed by the brain (43%). All patients with PCC received cytotoxic chemotherapy. Twelve patients had records of their response to cytotoxic chemotherapy; of these 12 patients, eight (8/12, 67%) achieved an objective response, and four (4/12, 33%) achieved stable disease response as the best response during chemotherapy. Conclusion It is known that most male PCC patients eventually develop resistance to cytotoxic chemotherapy and die. Factors such as poor response to chemotherapy, high disease burden, brain metastasis, and hemoptysis at the time of diagnosis are associated with shorter survival time in male PCC patients. Programmed death-1/programmed death-ligand 1 blockade therapy can be a salvage treatment for chemotherapy-resistant male PCC patients.
참고문헌 (17)
- Siddiqui BA, "Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment", Transl Androl Urol, 9(Suppl 1), pp.S56~S65 (2020)
- Chahoud J, "Managing extragonadal germ cell tumors in male adults", AME Med J, 5, pp.8~ (2020)
- Shen H, "Integrated molecular characterization of testicular germ cell tumors", Cell Rep, 23, pp.3392~3406 (2018)
- Rejlekova K, "Severe complications in testicular germ cell tumors : the choriocarcinoma syndrome", Front Endocrinol(Lausanne), 10, pp.218~ (2019)
- Stockton L, "Non-gestational choriocarcinoma with widespread metastases presenting with type 1 respiratory failure in a 39-year-old female : case report and review of the literature", Case Rep Oncol, 11, pp.151~158 (2018)
- Garrett A, "Pure nongestational ovarian choriocarcinoma : a scoping review", Integr Cancer Sci Ther, 4, pp.1~8 (2017)
- Jiang F, "Clinical analysis of 13 males with primary choriocarcinoma and review of the literature", Onco Targets Ther, 7, pp.1135~1141 (2014)
- Reilley MJ, "Testicular choriocarcinoma : a rare variant that requires a unique treatment approach", Curr Oncol Rep, 17, pp.2~ (2015)
- Pramod Darvin, "Immune checkpoint inhibitors: recent progress and potential biomarkers", Experimental and Molecular Medicine, 50, pp.1~11 (2018), 생화학분자생물학회
- Veras E, "PD-L1 ewxpression in human placentas and gestational trophoblastic diseases", Int J Gynecol Pathol, 36, pp.146~153 (2017)
- Ghorani E, "Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia", Lancet, 390, pp.2343~2345 (2017)
- Goldfarb JA, "A case of multi-agent drug resistant choriocarcinoma treated with pembrolizumab", Gynecol Oncol Rep, 32, pp.100574~ (2020)
- Huang M, "Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma", J Clin Oncol, 35, pp.3172~3174 (2017)
- Chi EA, "Durable response to immune checkpoint blockade in a platinum-refractory patient with nonseminomatous germ cell tumor", Clin Genitourin Cancer, 15, pp.e855~7 (2017)
- Loh KP, "Novel therapies in platinum-refractory metastatic germ cell tumor : a case report with a focus on a PD-1inhibitor", Rare Tumors, 9, pp.6867~ (2017)
- Han C, "A promising treatment option for refractory male primary choriocarcinoma : report of two cases", Transl Cancer Res, 9, pp.3054~3060 (2020)
- Adra N, "Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors : a Hoosier Cancer Research Network Study GU14-206", Ann Oncol, 29, pp.209~214 (2018)